(CMPS) Compass Pathways - Ratings and Ratios
Psilocybin Therapy, Depression Treatment, Mental Health
CMPS EPS (Earnings per Share)
CMPS Revenue
Description: CMPS Compass Pathways
Compass Pathways Plc is a UK-based biotechnology company focused on developing innovative treatments for mental health disorders, with a primary emphasis on its proprietary psilocybin therapy, COMP360. The companys pipeline includes ongoing Phase III clinical trials for treatment-resistant depression and Phase II trials for post-traumatic stress disorder (PTSD) and anorexia nervosa.
From a market perspective, Compass Pathways has garnered significant attention due to its pioneering work in psychedelic-assisted therapy. With a market capitalization of approximately $305 million USD, the companys stock (CMPS) has shown volatility, reflecting the high-risk, high-reward nature of biotech investments. Key performance indicators (KPIs) to watch include the progression of its clinical trials, particularly the outcome of its Phase III trial for treatment-resistant depression, as well as its cash burn rate and ability to secure future funding.
Notably, the companys return on equity (RoE) stands at -71.63%, indicating significant investment in research and development without current profitability. As Compass Pathways advances its clinical trials and potentially brings COMP360 to market, investors will be closely monitoring its revenue growth, R&D expenditure as a percentage of revenue, and overall progress toward achieving profitability. The companys ability to navigate regulatory hurdles and successfully commercialize its therapies will be crucial in determining its long-term success.
Looking ahead, potential catalysts for Compass Pathways include positive trial results, strategic partnerships, and regulatory approvals. Investors should keep a close eye on the companys cash position, as significant R&D expenses continue to impact its bottom line. Key metrics to monitor include the companys current cash balance, projected cash runway, and any potential financing initiatives.
CMPS Stock Overview
| Market Cap in USD | 485m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2020-09-18 |
CMPS Stock Ratings
| Growth Rating | -69.0% |
| Fundamental | 21.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -41.1% |
| Analyst Rating | 4.64 of 5 |
CMPS Dividends
Currently no dividends paidCMPS Growth Ratios
| Growth Correlation 3m | 77% |
| Growth Correlation 12m | -33.5% |
| Growth Correlation 5y | -93.7% |
| CAGR 5y | -26.59% |
| CAGR/Max DD 3y | -0.33 |
| CAGR/Mean DD 3y | -0.65 |
| Sharpe Ratio 12m | -0.63 |
| Alpha | 0.17 |
| Beta | 0.439 |
| Volatility | 68.72% |
| Current Volume | 1082.4k |
| Average Volume 20d | 1628.2k |
| Stop Loss | 4.6 (-8.7%) |
| Signal | -0.22 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-138.6m TTM) > 0 and > 6% of Revenue (6% = -8.30m TTM) |
| FCFTA -0.41 (>2.0%) and ΔFCFTA -5.62pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -177.1% (prev 6600 %; Δ -6777 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.51 (>3.0%) and CFO -148.3m <= Net Income -138.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (93.3m) change vs 12m ago 36.52% (target <= -2.0% for YES) |
| Gross Margin 100.1% (prev 28.76%; Δ 71.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover -48.38% (prev 1.32%; Δ -49.71pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -30.97 (EBITDA TTM -140.8m / Interest Expense TTM 4.56m) >= 6 (WARN >= 3) |
Altman Z'' -9.25
| (A) 0.83 = (Total Current Assets 276.4m - Total Current Liabilities 31.3m) / Total Assets 293.5m |
| (B) -2.01 = Retained Earnings (Balance) -591.0m / Total Assets 293.5m |
| warn (B) unusual magnitude: -2.01 — check mapping/units |
| (C) -0.49 = EBIT TTM -141.2m / Avg Total Assets 286.0m |
| (D) -4.62 = Book Value of Equity -604.6m / Total Liabilities 131.0m |
| Total Rating: -9.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 21.16
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -40.37% = -5.0 |
| 3. FCF Margin -86.12% = -7.50 |
| 4. Debt/Equity 0.20 = 2.48 |
| 5. Debt/Ebitda -0.23 = -2.50 |
| 6. ROIC - WACC (= -75.58)% = -12.50 |
| 7. RoE -78.53% = -2.50 |
| 8. Rev. Trend -4.37% = -0.33 |
| 9. EPS Trend 40.19% = 2.01 |
What is the price of CMPS shares?
Over the past week, the price has changed by -0.20%, over one month by +18.31%, over three months by +12.50% and over the past year by -30.19%.
Is Compass Pathways a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CMPS is around 3.90 USD . This means that CMPS is currently overvalued and has a potential downside of -22.62%.
Is CMPS a buy, sell or hold?
- Strong Buy: 7
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CMPS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.9 | 195.6% |
| Analysts Target Price | 14.9 | 195.6% |
| ValueRay Target Price | 4.3 | -14.5% |
Last update: 2025-09-12 04:33
CMPS Fundamental Data Overview
CCE Cash And Equivalents = 222.3m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -138.6m + Cost of Revenue 159.9k = -138.4m USD
P/B = 2.9806
Beta = 2.177
Revenue TTM = -138.4m USD
EBIT TTM = -141.2m USD
EBITDA TTM = -140.8m USD
Long Term Debt = 23.0m USD (from longTermDebt, last quarter)
Short Term Debt = 10.0m USD (from shortTermDebt, last quarter)
Debt = 33.0m USD (Calculated: Short Term 10.0m + Long Term 23.0m)
Net Debt = -187.0m USD (from netDebt column, last quarter)
Enterprise Value = 295.2m USD (484.5m + Debt 33.0m - CCE 222.3m)
Interest Coverage Ratio = -30.97 (Ebit TTM -141.2m / Interest Expense TTM 4.56m)
FCF Yield = -40.37% (FCF TTM -119.2m / Enterprise Value 295.2m)
FCF Margin = -86.12% (FCF TTM -119.2m / Revenue TTM -138.4m)
Net Margin = -100.1% (Net Income TTM -138.6m / Revenue TTM -138.4m)
Gross Margin = -100.1% ((Revenue TTM -138.4m - Cost of Revenue TTM 159.9k) / Revenue TTM)
Tobins Q-Ratio = -0.49 (set to none) (Enterprise Value 295.2m / Book Value Of Equity -604.6m)
Interest Expense / Debt = 3.53% (Interest Expense 1.16m / Debt 33.0m)
Taxrate = 21.0% (US default)
NOPAT = -141.2m (EBIT -141.2m, no tax applied on loss)
Current Ratio = 8.82 (Total Current Assets 276.4m / Total Current Liabilities 31.3m)
Debt / Equity = 0.20 (Debt 33.0m / last Quarter total Stockholder Equity 162.6m)
Debt / EBITDA = -0.23 (Net Debt -187.0m / EBITDA -140.8m)
Debt / FCF = -0.28 (Debt 33.0m / FCF TTM -119.2m)
Total Stockholder Equity = 176.4m (last 4 quarters mean)
RoA = -47.20% (Net Income -138.6m, Total Assets 293.5m )
RoE = -78.53% (Net Income TTM -138.6m / Total Stockholder Equity 176.4m)
RoCE = -70.79% (Ebit -141.2m / (Equity 176.4m + L.T.Debt 23.0m))
RoIC = -68.26% (NOPAT -141.2m / Invested Capital 206.8m)
WACC = 7.32% (E(484.5m)/V(517.5m) * Re(7.63%)) + (D(33.0m)/V(517.5m) * Rd(3.53%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 7.41%
Discount Rate = 7.63% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -119.2m)
EPS Correlation: 40.19 | EPS CAGR: 1.87% | SUE: 0.10 | # QB: 0
Revenue Correlation: -4.37 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for CMPS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle